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Sir, 
Mupirocin susceptibility in vitro and nasal eradication of epidemic 
methicillin-resistant Staphylococcus aureus 
In order to investigate the therapeutic efficacy of mupirocin we studied its 
activity in an outbreak of nosocomial infection due to methicillin-resistant 
Staphylococcus aweus (MRSA) in our hospital. 
Nasal carriers of MRSA were treated with calcium mupirocin nasal 
ointment 2% 8-hourly for seven days. From April 1990 until June 1992, 
MRSA isolates (nasal and/or cutaneous and/or pharyngeal) were obtained 
from 694 patients. Sixty-eight patients were colonized by MRSA with a 
MIC >4 mg 1-l of mupirocin. Of these, 75% had been colonized previously 
by susceptible strains. The MICs of these low-level mupirocin resistant 
strains ranged from 8 to 16 mg l-‘, and those of susceptible strains from 
0.06 to O-25 mg 1-l. 
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The mupirocin-resistant isolates were found in the intensive care unit and 
in three of the four hospital wards where MRSA carriers were isolated. 
We assessed the efficacy of mupirocin nasal treatment in bacterial 
eradication from this site, in patients colonized at multiple sites. Eradication 
was defined as negative nasal swabs taken at weekly intervals for three weeks 
after treatment. Table I compares nasal eradication in patients colonized in 
the nose alone with those colonized at multiple sites by strains with 
low-level mupirocin resistance. 
Although the difference in failure rates was not statistically significant, 
probably due to the small sample size, these data seem to indicate that 
colonization at multiple sites is clinically more important in failure of 
topical nasal treatment than low-level mupirocin resistance. 
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Table I. Response to mupirocin by resistant MRSA 
strains: comparison of response between patients colonized 
in nose alone with those colonized at multiple sites. 
Nose alone Multiple sites 
Eradication 12 (92%) 14 (61%) 
Persistence 1 9 
Total 13 23 
Fisher’s exact test P= 0.059. 
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